VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.
VBI has corporate headquarters at:
222 Third Street, Suite 2241
Cambridge, MA 02142
VBI was incorporated in April 1965. In May 2016, it changed its name to VBI Vaccines Inc.
VBI Vaccines Inc. is incorporated in British Columbia, Canada, with subsidiaries incorporated in Delaware, Ottawa (Canada), Israel, Hong Kong, and the Netherlands.
VBI Vaccines Inc. started trading publicly in May 2016.
Our fiscal year ends December 31st.
Our common stock is listed on the NASDAQ Market under the symbol “VBIV”.
You can purchase stock in our company through a registered brokerage or stock purchase service provider.
Through your brokerage account or by contacting our transfer agent.
250 Royall Street
Canton, MA 02021
Telephone: (781) 575-2000
111 Wood Avenue South
Iselin, NJ 08830-2700
Telephone: (732) 243-7000
U.S. Legal Counsel
Haynes Boone LLP
30 Rockefeller Plaza, 26th Floor
New York, NY 10112
Canadian Legal Counsel
5300 Commerce Court West
199 Bay Street
Toronto, Ontario M5L 1B9
For investor inquiring, please contact IR@vbivaccines.com.